Background: Subclavian vein thrombosis is a rare presentation of thoracic outlet syndrome (TOS). Typical treatment patterns consist of preoperative anticoagulation, followed by operative decompression by first rib resection and scalenectomy (FRRS). Recently, thrombolytic therapy has been used as the initial treatment with anticoagulation and FRRS. This study reviewed our extensive experience and compared the effectiveness of preoperative thrombolysis and venoplasty with anticoagulation alone in those undergoing FRRS to preserve subclavian vein patency. Methods: A retrospective review was conducted for all venous TOS patients from July 2003 to May 2009 from a prospectively maintained database. Patient demographics and use of preoperative anticoagulation, thrombolysis, and percutaneous venoplasty were recorded. Reports of follow-up venograms after FRRS were analyzed with regard to axillosubclavian vein patency, percutaneous venoplasty, results of intervention, and presence of occlusions. Postoperative clinic evaluations and duplex imaging reports were reviewed for presence of symptoms, recanalization, chronic nonocclusive thrombus, or continued complete occlusion. Results: A total of 103 patients (53 men, 50 women) had 110 FRRSs for subclavian vein thrombosis, seven of which had contralateral FRRS for thrombosis. The average age was 31 years (range, 16-54 years), with a mean follow-up of 13 months (range, 1-52 months). Overall before FRRS, 65 patients (59%) were managed with anticoagulation alone and 45 (41%) had preoperative endovascular interventions. Of these 45 patients, 22 (49%) underwent thrombolysis alone and 23 (51%) underwent thrombolysis and axillosubclavian balloon venoplasty. After FRRS, 43 patients (96%) had follow-up venograms 2 weeks postoperatively revealing patent subclavian veins in 15 patients, stenosis requiring balloon dilatation in 21, and occlusions in seven (16%). The overall initial patency rate in this group was 84%. In follow-up, recanalization was documented in five of the seven occlusions, with restoration of the patency of the subclavian vein at a mean of 2.8 months postoperatively (range, 1-6 months). In the 65 patients managed with anticoagulation alone before FRRS, 61 (94%) underwent follow-up venograms. The venograms revealed patent subclavian veins in 15 patients, stenosis requiring balloon dilatation in 36, and 10 occlusions (16%). Eight of 10 occlusions were recanalized at an average of 4.3 months (range, 1-11 months) after FRRS. Conclusions: Although initial treatment strategies for subclavian vein thrombosis may differ, a combination of anticoagulation, thrombolysis, operative decompression with FRRS, and postoperative endovascular interventions can yield excellent outcomes. A large proportion of patients in this series (41%) underwent thrombolysis before operative decompression with FRRS but showed no improvement in outcome as determined by vein patency on postoperative venography and duplex imaging during follow-up. Our large series suggests preoperative treatment with anticoagulation alone has vein patency rates similar to patients undergoing thrombolytic therapy. This treatment paradigm also has tremendous cost containment potential given the use of outpatient anticoagulation at the initial presentation has an obvious lower cost than an inpatient endovascular intervention. Overall, 106 of 110 of our patients (96%) had patent subclavian veins during our follow-up interval, were asymptomatic, and back to their previous active lifestyle.
Read full abstract